MILabs B.V. (Headquarters: The Netherlands, hereinafter MILabs), which joined the Rigaku Group in August 2021, is a leading global manufacturer of preclinical imaging systems. Preclinical research, as the name suggests, is a crucial step in the drug discovery process that usually uses mice and rats in advance of clinical trials on human. In preclinical research, efficacy, safety or toxicity of the drug candidates is assessed on living (in vivo) small animals, while visualization of experimental results allows researchers to comprehend how a drug works in organs or the full body with the help of imaging systems. MILabs provides such imaging systems with best-in-class accuracy, sensitivity and efficiency by virtue of developing its proprietary technologies, one of which being cylindrical multipinholes collimators.